The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. Shares traded 36% higher ahead of the morning ...

Shares of Apogee Therapeutics, Inc. APGE +46.5% + Free Alerts rose sharply in today's pre-market trading after the company ...